Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461952 · ClinicalTrials.gov registry record · Phase 2
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
A Phase 2 study, sponsored by Canadian Cancer Trials Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03461952 is a Phase 2 study that was terminated before completion, run by Canadian Cancer Trials Group. The registered enrollment target is 4 participants.
The verdict
NCT03461952, a Phase 2 study, was terminated before completion, sponsored by Canadian Cancer Trials Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab have been given to patients across multiple types of cancer, and safe doses and schedules have been determined.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2022-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03461952
The ClinicalTrials.gov registry entry for NCT03461952 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03461952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03461952 about?
NCT03461952 is a clinical study titled "Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)". The purpose of this study is to determine the safety and effectiveness of nivolumab alone or in combination with ipilimumab in patients with metastatic or unresectable tumors harbouring mutations in genes, POLE and POLD1. These mutations will be determined by plasma cfDNA. Nivolumab and ipilimumab h...
What is the current status of trial NCT03461952?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-03-11. Estimated completion is 2022-02-09.
What interventions are being tested in trial NCT03461952?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03461952?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.